Key Highlights

  • EPS fell short of consensus, underscoring earnings pressure.
  • Sales reached close to SEK 2.5 bn, reflecting a 4% currency‑adjusted increase.
  • EBITA of SEK 247 mn yielded a 10.1% margin despite rising raw‑material costs.
  • Cash flow improved to SEK 287 mn, indicating solid operational liquidity.

Nolato AB (OTC: NLTBF) posted earnings per share below consensus for the most recent quarter, while revenue climbed to close to SEK 2.5 bn, a 4% growth on a currency‑adjusted basis. EBITA stood at SEK 247 mn, delivering a margin of 10.1%.

EPS Shortfall vs Consensus

The earnings release showed EPS below the forecast compiled by analysts. Christer Wahlquist, president and CEO, acknowledged the shortfall while emphasizing the resilience of the sales top line. Per‑Ola Holmström, executive vice‑president and CFO, pointed to raw‑material cost inflation as a primary factor eroding earnings.

The 4% sales increase could not fully offset the margin compression, underscoring the need for tighter cost control to protect future profitability.

Revenue and EBITA Performance

Revenue for the quarter settled at close to SEK 2.5 bn, marking a 4% rise from the prior period on a currency‑adjusted basis. EBITA was reported at SEK 247 mn, translating into a 10.1% margin. Management explained that the margin decline stemmed from both elevated input costs and cash burn associated with new program start‑ups.

Cash flow, however, improved to SEK 287 mn, indicating healthy operational liquidity. The contrast between strong cash generation and compressed EBITA margin highlights a trade‑off that investors will monitor closely.

Segment Growth and Margin Pressures

The medical business area delivered the strongest growth, buoying overall revenue despite sector‑wide cost pressures. In contrast, other segments faced margin strain due to raw‑material price spikes and start‑up expenditures for new initiatives. Wahlquist highlighted that the medical segment’s performance could serve as a catalyst for long‑term earnings expansion if cost pressures ease.

Holmström warned that continued input‑price volatility may further compress margins if not mitigated. This dynamic suggests that segment‑specific execution will be key to sustaining profitability in the coming quarters.

Market Reaction and Outlook

Following the earnings release, the company’s shares experienced a modest decline, reflecting market disappointment over the EPS miss, even as cash flow strength provides a buffer. Investors will continue to assess the firm’s ability to improve margins and sustain growth ahead of the next earnings call. The upcoming quarter will be closely watched for signs that cost‑control measures and the momentum in the medical business area translate into stronger profitability.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.